

PHARMAXIS INVESTOR CONFERENCE CALL

BOEHRINGER INGELHEIM DEVELOPMENT PLANS FOR BI 1467335 IN NASH

Prior to the opening of the market tomorrow, 18 December 2019, Pharmaxis Ltd (PXS) will announce the advice the company has received from Boehringer Ingelheim (BI) concerning BI's future development plans for the drug it acquired from Pharmaxis in 2015. That announcement will have the effect of lifting the current trading halt over the company's shares.

The company will hold an investor teleconference at 9.15am (AEDT) tomorrow after release of the announcement.

Conference call details

Conference ID: 10003237

Access the call by one of three ways:

1. Pre-registration			
Participants can pre-register by navigating to: https://s1.c-conf.com/diamondpass/10003237-invite.html .			
Registered participants will receive their dial in number upon registration to enter the call automatically on the day.			
2. Dial-in directly (toll free)			
Australia:	1800 908 299	Japan:	0066 3386 8000
Sydney:	02 9007 8048	Malaysia:	1800 816 441
New Zealand:	0800 452 795	Singapore:	800 101 2702
Auckland:	+64 9 929 3905	South Africa:	0800 984 013
China:	10800 140 1776	Spain:	900 823 322
France:	0800 913 734	Switzerland:	0800 802 498
Germany:	0800 183 0918	Taiwan:	0080 112 7377
Hong Kong:	800 968 273	UAE:	8000 3570 2706
India:	0008 0010 08070	UK:	0800 051 1453
Indonesia:	007 803 321 8057	USA/Canada:	1 855 624 0077
Ireland:	1800 948 607		
Other International (Metered): +61 7 3145 4005			
3. Audio webcast link:			
https://services.choruscall.com.au/webcast/pharmaxis-191218.html			

A recording of the conference will be available on the Pharmaxis website Investor Centre page approximately 3 hours after the call.

#ENDS#

SOURCE: Pharmaxis Ltd, Sydney, Australia

AUTHORISED FOR RELEASE TO ASX BY:

David McGarvey, Chief Financial Officer and Company Secretary: T +61 2 9454 7203, E david.mcgarvey@pharmaxis.com.au

CONTACT:

Media: Felicity Moffatt: T +61 418 677 701, E felicity.moffatt@pharmaxis.com.au

Investor relations: Rudi Michelson (Monsoon Communications) T +61 411 402 737, E rudim@monsoon.com.au

About Pharmaxis

Pharmaxis Ltd is an Australian pharmaceutical research company and a global leader in drug development for inflammation and fibrotic diseases. The company has a highly productive drug discovery engine, drug candidates in clinical trials and significant future cash flows from partnering deals.

Leveraging its small-molecule expertise and proprietary amine oxidase chemistry platform, Pharmaxis has taken four in-house compounds to Phase 1 trials in just five years. Boehringer Ingelheim acquired the Pharmaxis anti-inflammatory AOC3 inhibitor in 2015 to develop it (BI 1467335) for two diseases: the liver condition Non-alcoholic Steatohepatitis (NASH) and diabetic retinopathy (DR).

The company's successor amine oxidase program has developed an oral anti-fibrotic LOXL2 inhibitor, aimed at NASH, pulmonary fibrosis (IPF) and other high-value fibrotic heart and kidney diseases, with a commercial partnering process underway. Two further new drugs from the same program are expected to begin proof-of-efficacy trials in 2020.

Pharmaxis' Mannitol platform has yielded the products Bronchitol® for cystic fibrosis, which is marketed in Europe, Russia and Australia, with United States FDA approval pending; and Aridol® for the assessment of asthma, which is sold in the United States, Europe, Australia and Asia.

Pharmaxis is listed on the Australian Securities Exchange (PXS). Its head office, manufacturing and research facilities are in Sydney, Australia. <http://www.pharmaxis.com.au/>

Forward-Looking Statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in partnering our LOXL2 program or any of the other products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.